181 related articles for article (PubMed ID: 38658775)
1. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial.
Hegde M; Navai S; DeRenzo C; Joseph SK; Sanber K; Wu M; Gad AZ; Janeway KA; Campbell M; Mullikin D; Nawas Z; Robertson C; Mathew PR; Zhang H; Mehta B; Bhat RR; Major A; Shree A; Gerken C; Kalra M; Chakraborty R; Thakkar SG; Dakhova O; Salsman VS; Grilley B; Lapteva N; Gee A; Dotti G; Bao R; Salem AH; Wang T; Brenner MK; Heslop HE; Wels WS; Hicks MJ; Gottschalk S; Ahmed N
Nat Cancer; 2024 Apr; ():. PubMed ID: 38658775
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
Turtle CJ; Hanafi LA; Berger C; Hudecek M; Pender B; Robinson E; Hawkins R; Chaney C; Cherian S; Chen X; Soma L; Wood B; Li D; Heimfeld S; Riddell SR; Maloney DG
Sci Transl Med; 2016 Sep; 8(355):355ra116. PubMed ID: 27605551
[TBL] [Abstract][Full Text] [Related]
3. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
[TBL] [Abstract][Full Text] [Related]
4. Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?
Filioglou D; Husnain M; Khurana S; Simpson RJ; Katsanis E
Front Immunol; 2023; 14():1329850. PubMed ID: 38077398
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
Ong SY; Pak S; Mei M; Wang Y; Popplewell L; Baird JH; Herrera AF; Shouse G; Nikolaenko L; Zain J; Godfrey J; Htut M; Aribi A; Spielberger R; Mansour J; Forman SJ; Palmer J; Budde LE
Am J Hematol; 2023 Nov; 98(11):1751-1761. PubMed ID: 37668287
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
Qu X; An G; Sui W; Wang T; Zhang X; Yang J; Zhang Y; Zhang L; Zhu D; Huang J; Zhu S; Yao X; Li J; Zheng C; Zhu K; Wei Y; Lv X; Lan L; Yao Y; Zhou D; Lu P; Qiu L; Li J
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100310
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Gauthier J; Bezerra ED; Hirayama AV; Fiorenza S; Sheih A; Chou CK; Kimble EL; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Jamieson AW; Bar M; Cassaday RD; Chapuis AG; Cowan AJ; Green DJ; Kiem HP; Milano F; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
Blood; 2021 Jan; 137(3):323-335. PubMed ID: 32967009
[TBL] [Abstract][Full Text] [Related]
8. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R; Jain N; Maus MV; Boissel N; Graham C; Jozwik A; Yallop D; Konopleva M; Frigault MJ; Teshima T; Kato K; Boucaud F; Balandraud S; Gianella-Borradori A; Binlich F; Marchiq I; Dupouy S; Almena-Carrasco M; Pannaux M; Fouliard S; Brissot E; Mohty M;
Lancet Haematol; 2022 Nov; 9(11):e833-e843. PubMed ID: 36228643
[TBL] [Abstract][Full Text] [Related]
9. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.
Ahmed N; Brawley V; Hegde M; Bielamowicz K; Kalra M; Landi D; Robertson C; Gray TL; Diouf O; Wakefield A; Ghazi A; Gerken C; Yi Z; Ashoori A; Wu MF; Liu H; Rooney C; Dotti G; Gee A; Su J; Kew Y; Baskin D; Zhang YJ; New P; Grilley B; Stojakovic M; Hicks J; Powell SZ; Brenner MK; Heslop HE; Grossman R; Wels WS; Gottschalk S
JAMA Oncol; 2017 Aug; 3(8):1094-1101. PubMed ID: 28426845
[TBL] [Abstract][Full Text] [Related]
10. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.
Heczey A; Louis CU; Savoldo B; Dakhova O; Durett A; Grilley B; Liu H; Wu MF; Mei Z; Gee A; Mehta B; Zhang H; Mahmood N; Tashiro H; Heslop HE; Dotti G; Rooney CM; Brenner MK
Mol Ther; 2017 Sep; 25(9):2214-2224. PubMed ID: 28602436
[TBL] [Abstract][Full Text] [Related]
11. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
Zhao WH; Liu J; Wang BY; Chen YX; Cao XM; Yang Y; Zhang YL; Wang FX; Zhang PY; Lei B; Gu LF; Wang JL; Yang N; Zhang R; Zhang H; Shen Y; Bai J; Xu Y; Wang XG; Zhang RL; Wei LL; Li ZF; Li ZZ; Geng Y; He Q; Zhuang QC; Fan XH; He AL; Zhang WG
J Hematol Oncol; 2018 Dec; 11(1):141. PubMed ID: 30572922
[TBL] [Abstract][Full Text] [Related]
12. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
Benjamin R; Graham C; Yallop D; Jozwik A; Mirci-Danicar OC; Lucchini G; Pinner D; Jain N; Kantarjian H; Boissel N; Maus MV; Frigault MJ; Baruchel A; Mohty M; Gianella-Borradori A; Binlich F; Balandraud S; Vitry F; Thomas E; Philippe A; Fouliard S; Dupouy S; Marchiq I; Almena-Carrasco M; Ferry N; Arnould S; Konto C; Veys P; Qasim W;
Lancet; 2020 Dec; 396(10266):1885-1894. PubMed ID: 33308471
[TBL] [Abstract][Full Text] [Related]
13. Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.
Lickefett B; Chu L; Ortiz-Maldonado V; Warmuth L; Barba P; Doglio M; Henderson D; Hudecek M; Kremer A; Markman J; Nauerth M; Negre H; Sanges C; Staber PB; Tanzi R; Delgado J; Busch DH; Kuball J; Luu M; Jäger U
Front Immunol; 2023; 14():1303935. PubMed ID: 38187393
[TBL] [Abstract][Full Text] [Related]
14. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
[TBL] [Abstract][Full Text] [Related]
15. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.
Ghilardi G; Chong EA; Svoboda J; Wohlfarth P; Nasta SD; Williamson S; Landsburg JD; Gerson JN; Barta SK; Pajarillo R; Myers J; Chen AI; Schachter L; Yelton R; Ballard HJ; Hodges Dwinal A; Gier S; Victoriano D; Weber E; Napier E; Garfall A; Porter DL; Jäger U; Maziarz RT; Ruella M; Schuster SJ
Ann Oncol; 2022 Sep; 33(9):916-928. PubMed ID: 35690221
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.
Shi D; Shi Y; Kaseb AO; Qi X; Zhang Y; Chi J; Lu Q; Gao H; Jiang H; Wang H; Yuan D; Ma H; Wang H; Li Z; Zhai B
Clin Cancer Res; 2020 Aug; 26(15):3979-3989. PubMed ID: 32371538
[TBL] [Abstract][Full Text] [Related]
18. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Ramos CA; Grover NS; Beaven AW; Lulla PD; Wu MF; Ivanova A; Wang T; Shea TC; Rooney CM; Dittus C; Park SI; Gee AP; Eldridge PW; McKay KL; Mehta B; Cheng CJ; Buchanan FB; Grilley BJ; Morrison K; Brenner MK; Serody JS; Dotti G; Heslop HE; Savoldo B
J Clin Oncol; 2020 Nov; 38(32):3794-3804. PubMed ID: 32701411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
